REGENXBIO Inc. said the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its biologics license application (BLA) for RGX-121 (clemidsogene lanparvovec), a one-time gene therapy candidate for Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
Pharm.D. from recognized University or equivalent institute. Renewed registration with Gujarat Pharmacy Council under the Pharmacy act, 1948 is must at the time of appointment.
Diploma in Ayurvedic Pharmacy from any recognised University / Institution or board or Faculty of Indian System of Medicine established by law in India and recognised by the Government.
M.Pharma-Master of Pharmacy / MSc Nursing Master of Science in Nursing with one year post-qualification experience in the field of research / Clinical Trial. Institute of Liver and Biliary Sciences, ILBS.
M.Sc. in Biotechnology / Life Sciences and must have qualified National Level JRF fellowship such as CSIR / UGC / DBT JRF and must have experience in pancreatic cancer biology. Regional Centre for Biotechnology
M.Sc / M.Pharm in Organic / Medicinal Chemistry. MSc / M.Pharm in any branch of Life Sciences with hands-on experience in organic compound synthesis may apply. National Institute of Immunology
Masters in any branch of Life Sciences from a recognized university. Experience in handling Mycobacterium tuberculosis clinical isolates will be preferable. National Institute of Immunology